<DOC>
	<DOCNO>NCT00806078</DOCNO>
	<brief_summary>This open label randomize single dose two-way crossover study compare bioavailability single oral dose quinine sulfate 648 mg ( 2 x 324 mg ) mix 120 ml chocolate pudding relative dose give two intact capsule .</brief_summary>
	<brief_title>Comparison Bioavailability Study Quinine Sulfate Chocolate Pudding</brief_title>
	<detailed_description>Prior study show intact quinine sulfate capsule take without regard food . This open label randomize single dose two-way crossover study compare bioavailability single oral dose quinine sulfate 648mg ( 2 x 324 mg capsule ) open mixed 120 ml chocolate pudding relative dose give two intact capsule . Eighteen healthy adult subject enrol . Following fast least 10 hour subject randomize receive either 648 mg quinine sulfate intact capsule open mixed 120ml chocolate pudding . Following washout period least 7 day subject give alternate dose similar condition . Following dose , blood sample collect time sufficient determine difference bioavailability ( ) two method drug administration . In addition patient monitor adverse event include Electrocardiogram ( EKG ) change ( baseline 4 hour dose ) .</detailed_description>
	<mesh_term>Quinine</mesh_term>
	<criteria>Healthy nonsmoking adult hemoglobin least 12 g/dl . Males least 52 kg , female least 45kg body mass index normal range , female must chemically surgically sterile postmenopausal ( amenorrhea least 2years ) Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 1year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease , myasthenia gravis , optic neuritis Glucose6phosphate dehydrogenase ( G6PD ) deficiency Prolonged correct QT interval ( QTc ) Electrocardiogram ( EKG ) screen male &gt; 430 msec , females &gt; 450 msec . PR interval EKG &gt; 200 msec screen prior dose either dose period Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 30 day prior first dose throughout study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>